Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.46 |
| ▸ | FBP1 | P09467 | 2/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7848638 | 0.96 | EGFR (0.45) | EGFRFBP1ERBB2KDRAURKA | |
| SCHEMBL7848647 | 0.96 | EGFR (0.45) | EGFRFBP1ERBB2KDRAURKA | |
| SCHEMBL27595565 | 0.88 | RAF1 (0.46) | EGFRFBP1ERBB2KDRAURKA | |
| SCHEMBL5690020 | 0.77 | EGFR (0.65) | EGFRERBB2KDRPDGFRBFLT4 | |
| SCHEMBL7850414 | 0.76 | EGFR (0.49) | EGFRERBB2PDGFRBERBB4 | |
| SCHEMBL29737288 | 0.76 | EGFR (0.59) | EGFRERBB2ERBB4 | |
| SCHEMBL17940125 | 0.76 | EGFR (0.50) | EGFRFBP1ERBB2KDRAURKA | |
| SCHEMBL17940086 | 0.74 | EGFR (0.51) | EGFRFBP1ERBB2KDRAURKA | |
| SCHEMBL16986930 | 0.74 | EGFR (0.56) | EGFRERBB2ERBB4 | |
| SCHEMBL3544316 | 0.73 | EGFR (0.55) | EGFRERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1633305-A | Pharmaceutical compositions based on anticholinergics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-06-29 | — | — | CN | disclosed |
| US-6740651-B2 | TREATING PARTICULARLY TUMORAL DISEASES, DISEASES OF THE LUNGS AND RESPIRATORY TRACT. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-05-25 | — | — | US | disclosed |
| US-20020115675-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | US | disclosed |
| CN-1341104-A | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-03-20 | — | — | CN | disclosed |
| EP-1157011-A1 | 4-AMINO- QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES | Boehringer Ingelheim Pharma KG (DE) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000051991-A1 | 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115675-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K20, MAP3K19 | EGFR 158/4885FBP1 2465/4885ERBB2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.